Actively Recruiting

Age: 18Years +
All Genders
NCT06817395

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Led by Massachusetts General Hospital · Updated on 2025-02-10

100

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

Sponsors

M

Massachusetts General Hospital

Lead Sponsor

P

Platelet Disorder Support Association (PDSA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants will take a cognitive function test and complete surveys on quality of life, fatigue, depression, and cognitive symptoms. The primary aim of the study is to evaluate for the presence and extent of cognitive impairment in patients with ITP. The study will also assess whether cognitive impairment in ITP is associated with patient-reported impacts on quality of life, fatigue, mood, and cognitive symptoms as well as clinical characteristics such as ITP disease and treatment history.

CONDITIONS

Official Title

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 218 years or older
  • Clinical diagnosis of persistent or chronic ITP with platelet counts <50 x 10^9/L on two occasions in the past 3 to 12 months or >12 months, respectively
  • Documented response to at least one prior ITP-directed therapy such as corticosteroids, intravenous immune globulin, Rho(D) immune globulin, splenectomy, thrombopoietin receptor agonists, or fostamatinib
  • Ability to follow instructions in English
Not Eligible

You will not qualify if you...

  • Pre-existing diagnosis of cognitive impairment due to dementia, stroke, or other neurological disease
  • Active psychiatric disorder including uncontrolled major depression, schizophrenia, severe anxiety, or active alcohol or drug abuse
  • Active cancer requiring or expected to require chemotherapy or surgery, except non-melanoma skin cancer
  • Brain tumor or cranial surgery within the past year
  • Significant hearing or vision impairment preventing completion of neurocognitive testing via a virtual platform

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

Loading map...

Research Team

D

Debbie Jiang, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here